• Medtronic has recently begun the commercial rollout across Europe of its MiniMed Go Smart MDI system, which combines data from the InPen smart insulin pen and Simplera continuous glucose sensor into a single mobile app for people managing diabetes with multiple daily injections.
• This integrated solution marks a meaningful step in connecting insulin delivery and glucose monitoring data, potentially improving day-to-day decision support for European diabetes patients who are not using insulin pumps.
• We’ll now examine how this integrated smart MDI and sensor launch could influence Medtronic’s investment narrative around diabetes and digital health.

Invest in the nuclear renaissance through our list of 85 elite nuclear energy infrastructure plays powering the global AI revolution.

Medtronic Investment Narrative Recap

To own Medtronic, you generally need to believe in durable demand for its medical devices, especially in chronic disease and digital health, while accepting execution and margin risks from its broad innovation push. The MiniMed Go Smart MDI launch in Europe strengthens the diabetes and digital health story, but it does not materially change the near term focus on improving gross margins and executing complex product ramp ups across key growth platforms.

The most relevant recent announcement alongside MiniMed Go is Medtronic’s continued investor outreach, including upcoming CFO fireside chats at major healthcare conferences, which keeps the market closely informed on progress across diabetes and digital ecosystems. For investors tracking catalysts, these forums can help clarify how launches like MiniMed Go fit into the broader transformation agenda, including the planned Diabetes separation and the company’s efforts to lift earnings quality and consistency.

Yet, while this new diabetes product strengthens the story, investors still need to be aware of...

Medtronic’s narrative projects $40.0 billion revenue and $6.3 billion earnings by 2028. This requires 5.4% yearly revenue growth and a roughly $1.6 billion earnings increase from $4.7 billion today.

Uncover how Medtronic's forecasts yield a $111.77 fair value, a 16% upside to its current price.

Exploring Other Perspectives

Nine fair value estimates from the Simply Wall St Community cluster between US$94.77 and US$111.77 per share, underscoring how differently individual investors assess Medtronic. You should weigh those views against ongoing risks that heavy R&D and commercial ramp spending may outpace returns if launches like MiniMed Go or other new systems do not gain sufficient traction.

Explore 9 other fair value estimates on Medtronic - why the stock might be worth as much as 16% more than the current price!

Reach Your Own Conclusion

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Medtronic research is our analysis highlighting 5 key rewards that could impact your investment decision.
• Our free Medtronic research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Medtronic's overall financial health at a glance.

Ready For A Different Approach?

Every day counts. These free picks are already gaining attention. See them before the crowd does:

• Explore 22 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.
• Uncover the next big thing with 32 elite penny stocks that balance risk and reward.
• AI is about to change healthcare. These 31 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.